AR002974A1 - Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista. - Google Patents

Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.

Info

Publication number
AR002974A1
AR002974A1 AR10192896A AR10192896A AR002974A1 AR 002974 A1 AR002974 A1 AR 002974A1 AR 10192896 A AR10192896 A AR 10192896A AR 10192896 A AR10192896 A AR 10192896A AR 002974 A1 AR002974 A1 AR 002974A1
Authority
AR
Argentina
Prior art keywords
antagonist
cosmetic
pharmaceutical
preparation
treatment procedure
Prior art date
Application number
AR10192896A
Other languages
English (en)
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR002974(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Publication of AR002974A1 publication Critical patent/AR002974A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
AR10192896A 1995-03-28 1996-03-27 Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista. AR002974A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503628A FR2732221B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue

Publications (1)

Publication Number Publication Date
AR002974A1 true AR002974A1 (es) 1998-05-27

Family

ID=9477498

Family Applications (1)

Application Number Title Priority Date Filing Date
AR10192896A AR002974A1 (es) 1995-03-28 1996-03-27 Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.

Country Status (15)

Country Link
US (2) US5932215A (es)
EP (1) EP0734729B2 (es)
JP (1) JPH08268874A (es)
AR (1) AR002974A1 (es)
AT (1) ATE168011T1 (es)
BR (1) BR9601478A (es)
CA (1) CA2172777C (es)
DE (1) DE69600399T3 (es)
DK (1) DK0734729T4 (es)
ES (1) ES2121461T5 (es)
FR (1) FR2732221B1 (es)
HU (1) HUP9600765A3 (es)
MX (1) MX9601150A (es)
PL (1) PL313515A1 (es)
RU (1) RU2152798C1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
MXPA03009995A (es) * 2001-05-09 2004-06-30 Univ Michigan Uso de composiciones para tratar rosacea.
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
EA008744B1 (ru) * 2002-08-12 2007-08-31 Актавис Груп Хф. Применение соединений антагонистов кальцитонин генсвязанного пептида (cgrp) для лечения псориаза
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1809104A4 (en) * 2004-09-23 2009-04-29 Alexander Michalow METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATIONS
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
PT2380592T (pt) 2005-11-14 2018-06-06 Teva Pharmaceuticals Int Gmbh Anticorpos antagonistas dirigidos contra o péptido relacionado com o gene da calcitonina e métodos utilizando os mesmos
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
US8367122B2 (en) * 2008-06-11 2013-02-05 Biochemics, Inc. Control of blood vessel physiology to treat skin disorders
BRPI0918142A2 (pt) 2008-09-10 2015-12-01 Biochemics Inc composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico
MX349176B (es) * 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
WO2010065922A2 (en) 2008-12-04 2010-06-10 Biochemics, Inc. Methods and compositions for tattoo removal
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
EP2542246A1 (en) * 2010-03-03 2013-01-09 Neocutis SA Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
HUE033143T2 (en) 2010-03-26 2017-11-28 Galderma Res & Dev Preparations containing brimonidine for the treatment of erythema
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
SG194974A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
EP2710039B1 (en) 2011-05-20 2019-01-09 AlderBio Holdings LLC Anti-cgrp compositions and use thereof
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
FR3030521B1 (fr) 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2017001433A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
KR20210113597A (ko) 2019-01-08 2021-09-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 두통의 급성 치료 및 신속 치료

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
TW263498B (es) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
CZ286758B6 (en) * 1994-03-21 2000-06-14 Thomsen John Brown Pharmaceutical preparation in the form of a gel for treating skin diseases
ATE228834T1 (de) * 1994-09-30 2002-12-15 Oreal Verwendung von einem agonisten eines mit einem chloridkanal assozierten rezeptors zur behandlung von hautfalten
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728265A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
EP0734729B1 (fr) 1998-07-08
DE69600399T3 (de) 2005-07-14
PL313515A1 (en) 1996-09-30
ES2121461T5 (es) 2005-05-01
BR9601478A (pt) 1998-06-02
ES2121461T3 (es) 1998-11-16
EP0734729B2 (fr) 2004-09-29
HUP9600765A2 (en) 1997-06-30
FR2732221B1 (fr) 1997-04-25
DE69600399D1 (de) 1998-08-13
CA2172777A1 (fr) 1996-09-29
RU2152798C1 (ru) 2000-07-20
US6509014B1 (en) 2003-01-21
HUP9600765A3 (en) 1998-04-28
DK0734729T3 (da) 1999-04-19
DE69600399T2 (de) 1998-10-29
US5932215A (en) 1999-08-03
MX9601150A (es) 1997-02-28
ATE168011T1 (de) 1998-07-15
FR2732221A1 (fr) 1996-10-04
HU9600765D0 (en) 1996-05-28
DK0734729T4 (da) 2004-10-25
CA2172777C (fr) 2007-07-24
EP0734729A1 (fr) 1996-10-02
JPH08268874A (ja) 1996-10-15

Similar Documents

Publication Publication Date Title
AR002974A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.
DE69512685D1 (de) Mittel zur verabreichung von wirksubstanzen an bzw. durch die haut
BR9711098B1 (pt) compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
PL312481A1 (en) Application of cgrp antagonist in cosmetic, pharmaceutical or dermatological composition and so obtained composition as such
BR0005786B1 (pt) composiÇço de cosmÉtico para o tratamento de cabelo ou pele.
RU93048466A (ru) Применение бензотиофенов для профилактики и лечения остеопороза и фармацевтическая композиция на их основе
AR009356A1 (es) Compuesto de 1-4 heterociclico, inhibidor de la metaloproteasa y su uso para preparar una composicion farmaceutica y para prevenir o tratar una enfermedad asociada con la actividad de la metalo proteasa y la caquexia
PT1181027E (pt) Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
BR9903336B1 (pt) composição cosmética, usos da composição e processo para o tratamento cosmético de substáncias queratìnicas.
EP0824915A3 (de) Herstellung von Glycoglycerolipiden, deren Verwendung als Tenside sowie kosmetische oder dermatologische Zubereitungen, solche Glycoglycerolipide enthaltend
WO2002060391A3 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
BR9506581A (pt) Composto composição farmacêutica uso do composto processo para a profilaxia ou tratamento de uma condição clínica em um manífero por exemplo um humano e para a preparação de um composto e composto intermediário
AR004326A1 (es) Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.
PT1001792E (pt) Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
EE9900162A (et) Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine
BR0200921A (pt) Uso de produtos de legume para o tratamento de agressões externas
BR9709154A (pt) Utilização de um inibidor da atividade do ácido retinóico em uma composição cosmética ou para a preparação de uma composição farmacêutica
ES2159697T3 (es) Utilizacion de un antagonista de cgrp para tratar los liquenes y los pruritos y composicion obtenida.
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
FR2723316B1 (fr) Compositions et preparations depigmentantes de la peau, a usages pharmaceutiques ou cosmetiques
BR9706889A (pt) Uso de extratos de ginkgo biloba para a preparação de composições farmacêuticas e processo de tratamento cosmético usando um extrato de ginkgo biloba
AR002975A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparaciónde una composición farmacéuticao dermatológica para tratar los pruritos, algias y/o disestesias oculares y/o palpebrales como asi tambien en una composición cosmética para ojos sensibles, composición obenida y procedimiento empleando dicha composición cosmética.
FR2728465B1 (fr) Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de smelophyllum capense
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.